Bacterial resistance studies using in vitro dynamic models: The predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4956-4962

  Firsov, Alexander A ^a   Strukova, Elena N ^a   Shlykova, Darya S ^a   Portnoy, Yury A ^a   Kozyreva, Varvara K ^b   Edelstein, Mikhail V ^b   Dovzhenko, Svetlana A ^a   Kobrin, Mikhail B ^a   Zinner, Stephen H ^c  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b SMOLENSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^c MOUNT AUBURN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; BROTH DILUTION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG HALF LIFE; ESCHERICHIA COLI; IN VITRO STUDY; KERNEL METHOD; MINIMUM INHIBITORY CONCENTRATION; MUTANT PREVENTION CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; PRIORITY JOURNAL; SPECIES COMPARISON; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; MUTATION; QUINOLONES;

EID: 84884237443     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00578-13     Document Type: Article

References (16)

1. Dong Y, Zhao X, Domagala J, Drlica K. 1999. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43: 1756-1758.
2. Firsov AA, Smirnova MV, Strukova EN, Vostrov SN, Portnoy YA, Zinner SH. 2008. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. Int. J. Antimicrob. Agents 32:488-493.
3. Liang B, Bai N, Cai Y, Wang R, Drlica K, Zhao X. 2011. Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacinresistant subpopulations of Staphylococcus aureus. Antimicrob. Agents Chemother. 55:2409-2412.
4. Olofsson SK, Marcusson LL, Lindgren PK, Hughes D, Cars O. 2006. Selection of ciprofloxacin resistance of Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J. Antimicrob. Chemother. 57:1116-1121.
5. Croisier D, Etienne M, Piroth L, Bergoin E, Lequeu C, Portier H, Chavanet P. 2004. Iin vivo pharmacodynamics efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J. Antimicrob. Chemother. 54:640-647.
6. Gebru E, Choi M-J, Lee S-J, Damte D, Park SC. 2011. Mutantprevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/ marbofloxacin-selected mutants of Escherichia coli of canine origin. J. Med. Microbiol. 60:1512-1522.
7. Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH. 2006. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J. Antimicrob. Chemother. 58:1185-1192.
8. Fowler RG, Degnen GE, Cox EC. 1974. Mutational specificity of a conditional Escherichia coli mutator, mutD5. Mol. Gen. Genet. 133: 179 -191.
9. Firsov AA, Vostrov SN, Shevchenko AA, Cornaglia G. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287.
10. Wilson APR, Grüneberg RN. 1997. Ciprofloxacin: 10 years of clinical experience. Maxim Medical, Oxford, United Kingdom.
11. Firsov AA, Chernykh VM, Navashin SM. 1990. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrob. Agents Chemother. 34:1312-1317.
12. MacGowan AP, Bowker KE, Wootton M, Holt HA. 1999. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection. Antimicrob. Agents Chemother. 43:1560-1564.
13. Sáenz Y, Zarazaga M, Briñas L, Ruiz-Larrea F, Torres C. 2003. Muta- tions in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans, and animals. J. Antimicrob. Chemother. 51:1001-1005.
14. Smirnova MV, Vostrov SN, Strukova EN, Dovzhenko SA, Kobrin MB, Portnoy YA, Zinner SH, Firsov AA. 2009. The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models. J. Antimicrob. Chemother. 64:815-820.
15. Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. 1992. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 36:993-996.
16. Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.